Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3303917 | 1.00 | MEN1 (0.36) | MEN1KMT2AMAPTFKBP1ANFKB1 | |
| SCHEMBL7058824 | 0.88 | ALDH1A1 (0.32) | KMT2AMAPTFKBP1ACYP3A4ALDH1A1 | |
| SCHEMBL3302863 | 0.88 | ALDH1A1 (0.32) | KMT2AMAPTFKBP1ACYP3A4ALDH1A1 | |
| SCHEMBL25475425 | 0.88 | ALDH1A1 (0.32) | KMT2AMAPTFKBP1ACYP3A4ALDH1A1 | |
| SCHEMBL24165696 | 0.88 | PTPN1 (0.34) | MEN1KMT2ANR1H2CYP1A2POLB | |
| SCHEMBL24165697 | 0.88 | PTPN1 (0.34) | MEN1KMT2ANR1H2CYP1A2POLB | |
| SCHEMBL24165981 | 0.87 | TLR2 (0.35) | MEN1KMT2AFKBP1ANR1H2P2RX3 | |
| SCHEMBL25475444 | 0.87 | TLR2 (0.35) | MEN1KMT2AFKBP1ANR1H2P2RX3 | |
| SCHEMBL24166233 | 0.86 | POLB (0.33) | MEN1KMT2ANR1H2CYP1A2POLB | |
| SCHEMBL25475445 | 0.86 | POLB (0.33) | MEN1KMT2ANR1H2CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4175635-B1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF | SEA PHARMACEUTICALS LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | Sea Pharmaceuticals LLC. (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2023130008-A2 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | SEA PHARMACEUTICALS LLC (US) | 2023-07-06 | — | — | WO | disclosed |
| US-11685726-B2 | Pharmaceutical compositions of 6-(2-(2H-tetrazol-5-yl)ethyl)-6-fluorodecahydroisoquinoline-3-carboxylic acid and ester derivatives thereof | SEA PHARMACEUTICALS LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685726-B2 | Pharmaceutical compositions of 6-(2-(2H-tetrazol-5-yl)ethyl)-6-fluorodecahydroisoquinoline-3-carboxylic acid and ester derivatives thereof | SEA PHARMACEUTICALS LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685726-B2 | Pharmaceutical compositions of 6-(2-(2H-tetrazol-5-yl)ethyl)-6-fluorodecahydroisoquinoline-3-carboxylic acid and ester derivatives thereof | SEA PHARMACEUTICALS LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230150971-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF | SEA PHARMACEUTICALS LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150971-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF | SEA PHARMACEUTICALS LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150971-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF | SEA PHARMACEUTICALS LLC (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4175635-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF | Sea Pharmaceuticals LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| WO-2022006537-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF | SEA PHARMACEUTICALS LLC (US) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074887-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF | GABRQ, GRIK5, CYP3A7 | MEN1 1622/4885KMT2A 1192/4885MAPT 329/4885 |
| US-11685726-B2 | Pharmaceutical compositions of 6-(2-(2H-tetrazol-5-yl)ethyl)-6-fluorodecahydroisoquinoline-3-carboxylic acid and ester derivatives thereof | KCNQ5, KCNQ2, KCNQ3 | MEN1 2770/4885KMT2A 1625/4885MAPT 1166/4885 |
| US-20230150971-A1 | PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF | KCNQ5, KCNQ2, KCNQ3 | MEN1 2770/4885KMT2A 1625/4885MAPT 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.